Neurology

Galcanezumab Effective at Decreasing Monthly Headache Days in Migraine




Approximately 40% of patients with episodic migraine who were treated with galcanezumab achieved 100% response rate for at least 1 month.

Source link






Related posts

Visual Dysfunction: An Underrecognized Symptom of Parkinson's?

Newsemia

Association of alcohol dehydrogenase and aldehyde dehydrogenase Polymorphism with Spontaneous Deep Intracerebral Haemorrhage in the Taiwan population

Newsemia

New AAN Guidelines for the Management of Disorders of Consciousness

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy